Shenzhen People' S Hospital
Shenzhen, Guangdong, 518000, China
NCT Number: NCT04426422
This study was aimed to investigate the effect of metformin on the gut microbiota and glycemic control in newly diagnosed type 2 diabetes patients.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
Shenzhen, Guangdong, 518000, China
This study was aimed to investigate the effect of metformin on the gut microbiota and glycemic control in newly diagnosed type 2 diabetes patients. All the recurited patients were treated with metformin 1500-2000mg daily for 3 months. Stool specimens and blood samples were collected at the beginning and 3 months later.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
newly diagnosis type 2 diabetes ,HbA1c >7 %
Exclusion criteria
history of cardiovascular disease, hypertension, severe renal dysfunction defined as glomerular filtration rate < 45 mL/min/1.73 m2; severe illness or diabetic ketoacidosis within 30 days, inability to tolerate ≥500 mg metformin twice per day and pregnancy.
treated with metformin 1500-2000mg daily
Other names: intervention group
Time frame: 3 months
the changes of gut micribiota
Time frame: 3 months
HbA1c
Shenzhen People's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06649773
Diabetes Mellitus, Diabetes Mellitus, Type 2
Beijing, Beijing Municipality, China
View Trial DetailsNCT05530356
Adolescent Obesity, Body Weight
Aurora, Colorado, United States
View Trial DetailsNCT06626646
Arterial Occlusive Diseases, Arteriosclerosis
North York, Ontario, Canada
View Trial DetailsNCT07005362
Artificial Intelegence, Behavior
Aurora, Colorado, United States
View Trial Details